Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Bernstein Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$1,425,155

183 payments

Through program year 2025, Bernstein Clinical Research is reported as receiving $1,425,155 in research payments, across 183 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $110,906 4
2024 Research $79,867 5
2023 Research $86,822 5
2022 Research $218,302 48
2021 Research $219,569 25
2020 Research $160,229 23
2019 Research $549,460 73

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $912,650 47 payments
  2. GlaxoSmithKline, LLC. $188,736 65 payments
  3. Shire North American Group Inc $153,861 41 payments
  4. AstraZeneca UK Limited $69,060 6 payments
  5. Regeneron Pharmaceuticals, Inc. $42,032 13 payments
  6. AstraZeneca AB $36,910 4 payments
  7. Octapharma USA, Inc. $17,610 5 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $4,295 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $172,972 4 payments
  2. A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler $160,598 9 payments
  3. A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma $148,010 7 payments
  4. Help Study Extensiontm An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Dx-2930 for Prevention Against Acute Attacks of Hereditary Angioedema Hae $146,161 34 payments
  5. A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma. $113,743 8 payments
  6. A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma $107,725 2 payments
  7. A Phase 2b Multinational Randomised Double-blind Parallelgroup 24-week Placebo-controlled Study with 28-week Extension to Investigate the Use of Benralizumab in Patients with Moderate to Severe Chronic Spontaneous Urticaria $69,060 6 payments
  8. Study to evaluate the efficacy and safety of Tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma $67,610 6 payments
  9. A Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma $63,222 6 payments
  10. A Multicenter, Randomized, Open-label, Parallel group, Functionality, and Performance Study of an Accessorized Pre-filled Syringe and Autoinjector with Home-administered Tezepelumab in Adolescent and Adult Subjects with Severe Asthma $62,844 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record